UK regulatory clearance opens NeuroStrip commercial pathway
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has registered Control Bionics’ (ASX: CBL) wearable surface electromyography (sEMG) device, NeuroStrip. The registration clears the primary regulatory hurdle for commercial supply across England, Scotland and Wales.
MHRA registration confirms Control Bionics’ status as a registered medical device manufacturer, enabling the company to pursue commercial supply and revenue generation across Great Britain. The clearance opens a well-established, well-funded new market and moves the neurotechnology company a step closer from regulatory approval toward commercial execution.
When big ASX news breaks, our subscribers know first
What the MHRA registration unlocks
The registration confirms Control Bionics as a registered medical device manufacturer and enables commercial supply across England, Scotland and Wales. NeuroStrip is registered in the Global Medical Device Nomenclature (GMDN) under code 63697 and classified as a psychophysiological biofeedback system.
The UK offers what the company describes as a well-established and well-funded rehabilitation and research sector, alongside elite sports markets. Each represents a potential application channel for NeuroStrip in a credible near-term revenue market.
This development builds on Control Bionics’ existing regulatory footprint. The company already holds clearances in the US, Australia and Europe, so the UK registration extends an established international position rather than marking a first clearance.
Addressable UK applications for NeuroStrip include:
-
Rehabilitation
-
Research
-
Elite and professional sports performance
The rehabilitation and research sector is characterised by stable institutional funding, which positions it as a plausible early revenue channel for the device.
Early trials already underway
Three pilot programmes demonstrating the device’s clinical and performance value are already underway, with several additional customer trials due to start in September 2026. These early engagements are intended to validate NeuroStrip across clinical and performance settings ahead of broader commercial supply.
Initial customers include:
-
Dr. Tom Maden-Wilkinson (University of Lancaster and University of Sheffield), described as “a world leading expert in sEMG”
-
University of Nottingham
-
British Olympics
Feedback from these users will form a core component of the company’s sales-conversion strategy. The insights are expected to inform Control Bionics’ UK market-entry approach, as well as broader expansion across Europe.
Trials with credible academic and sporting institutions help de-risk market entry and support the transition from clearance to commercial supply.
CEO Commentary
“UK registration is another milestone in our ongoing global commercial expansion. The UK is a key commercial market for NeuroStrip, and we are moving quickly from regulatory clearance to commercial execution. Combined with our US FDA registration, we are building the foundations to scale NeuroStrip across major international markets,” said Jeremy Steele, CEO and Managing Director.
Understanding NeuroStrip and sEMG technology
Surface electromyography (sEMG) is a non-invasive way to capture the electrical activity generated by muscles. It measures these signals from the skin’s surface, without breaking the skin barrier.
A defining feature of NeuroStrip is that it is wearable and “does not require surgery or implantation.” This lowers the barrier to adoption across clinical, research and performance environments.
Control Bionics operates a single underlying neural-signal platform serving four applications: Performance, Rehabilitation, Research & Data, and Assistive Communication. The technology has historically been deployed in assistive communication and is now being extended into these additional fields, representing an extension of an existing platform rather than a first-time deployment.
For investors, a single platform supporting multiple revenue verticals points to a scalable addressable market. The table below outlines how each application maps to UK opportunity.
| Application | Description | UK Market Relevance |
|---|---|---|
| Performance | Sports and elite performance | British Olympics trial |
| Rehabilitation | Clinical recovery | Well-funded UK rehabilitation sector |
| Research & Data | Measurable outcomes | University trials |
| Assistive Communication | Historical core use | Established base |
Building an international commercial footprint
The UK milestone sits within Control Bionics’ broader global expansion strategy, which the company links to its US FDA registration. Management has framed the registration as part of an ongoing effort to scale NeuroStrip across major international markets.
The company already holds regulatory clearances in the US, Australia and Europe, and is a registered NDIS provider in Australia. The next phase centres on converting active trials into commercial supply, launching additional customer trials from September 2026, and pursuing broader European expansion.
FDA registration for NeuroStrip, secured in August 2026, established the platform’s US medical device status and opened formal access to clinical rehabilitation providers and research institutions across America, providing the closest parallel to what MHRA registration now unlocks in Great Britain.
The stated next steps are:
-
Complete three active UK pilot programmes
-
Launch additional customer trials from September 2026
-
Use feedback to drive sales conversion and UK market entry
-
Extend expansion across Europe
Regulatory clearance in a major, well-funded market, combined with active institutional trials, positions Control Bionics to work toward moving from clearance to revenue across multiple verticals. With clearances now spanning the US, Australia, Europe and Great Britain, the company is assembling the regulatory foundations for a wider international footprint, though the pace of commercial conversion remains dependent on trial outcomes and market execution.
For readers wanting broader context on how the UK registration fits within the company’s simultaneous multi-market push, our full explainer on CBL’s four-market commercial expansion covers the US distribution partnerships, European insurance wins, elite sports trials, and Apple BCI integration all progressing in parallel during 2026.
Don’t Miss the Next Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ investors who never miss a market-moving announcement. Click the “Free Alerts” button to start receiving real-time coverage the moment ASX healthcare stocks make their move.